Non-cardioembolic cerebral infarction
Conditions
Interventions
Antiplatelet monotherapy (excluding cilostazol) and statin monotherapy Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administrated once daily. Statin (atorvastatin 10mg, pitava
Sponsors
Department of Neurology, Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with a diagnosis of noncaridioembolic IS that developed within 7 days before the start of the protocol treatment Patients with a responsible lesion identified by MRI Patients with dyslipidemia (total chlolesterol > 6.0nmol/L) or under the treatment of dyslipidemia Patients taking clopidogrel or aspirin as antiplatelet therapy when providing informed consent Patients aged 40 to 85 years old when providing informed consent Patients considered to be able to visit the study site Patients who provided written informed consent
Exclusion criteria
Exclusion criteria: Patients with a history of acute myocardial infarction within six months Patients with congestive heart failure or uncontrolled angina pectoris Patients with a history of caridiovascular angioplasty within six months Patients with severe liver or renal dysfunction Patients with a malignant tumor requiring treatment Patients with uncontrolled diabetes mellitus Patients with secondary dyslipidemia (due to corticosteroid etc) Patients with hemorrhagic diseases (eg. Hemophilia, hemorrhagic intestinal diseases, hemorrhage from gastrointesitinal tract and urinary tract, hemoptysis) Patients with hypersensitivity to aspirin, clopidogrel or cilostazol Patients scheduled to undergo any surgery during the study period Patients considered by the investigator/subinvestigator to be unsuitable for participating in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of symptomatic ischemic stroke, with the symptoms lasting for at least 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Any stroke [ischemic stroke (IS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)] IS or transient ischemic attack (TIA) ICH or SAH Death from any cause Stroke (IS, ICH, SAH), myocardial infarction (MI), or vascular events All vascular events: stroke, MI, and other vascular events Adverse events and adverse drug reactions Severe or life-threatening hemorrhage (GUSTO Criteria) | — |
Countries
Japan
Contacts
Public ContactHiroo Terashi
Tokyo Medical University Department of Neurology
Outcome results
None listed